Investors & Media
Medical Affairs
Contact
Abstract 3D model of connected blue and white spheres representing a molecular structure.

Publications

Explore our peer-reviewed research

For more peer-reviewed articles, congress presentations, and medical information resources intended for U.S. healthcare professionals, please visit the Vera Therapeutics Medical Affairs website.

Updating results…
6 results found

  • 2026

    Atacicept: dual BAFF/APRIL inhibition and clinical evidence in IgA nephropathy

    Barratt J, Lafayette R. Future Rare Diseases

    Read more

  • 2026

    Microscopic hematuria in IgA nephropathy: a biomarker of disease activity

    Floege J, et al. Clinical Kidney Journal

    Read more

  • 2026

    A plain language summary: long-term safety and effectiveness of atacicept in individuals with IgA nephropathy

    Barratt J, et al. Current Medical Research and Opinion

    Read more

  • 2025

    A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy

    Lafayette R, et al. New England Journal of Medicine

    Read more

  • 2024

    Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy

    Barratt J, et al. Journal of the American Society of Nephrology

    Read more

  • 2024

    A Phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy

    Lafayette R, et al. Kidney International

    Read more

Leaving this site

The link will take you to a third-party site that is not owned or controlled by Vera Therapeutics. Vera Therapeutics makes no representation as to the accuracy of the information contained on third-party sites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.